
|Videos|June 11, 2021
Pharmacist Medication Insights: Dupilumab for Atopic Dermatitis, Asthma
Author(s)Saro Arakelians, PharmD
Dupilumab is a fully human monoclonal antibody that inhibits the signaling of the interleukin-4 (IL-4) and interleukin-13 (IL-13) proteins.
Advertisement
Dupilumab is a fully human monoclonal antibody that inhibits the signaling of the interleukin-4 (IL-4) and interleukin-13 (IL-13) proteins. Data from dupilumab clinical trials have shown that IL-4 and IL-13 are key drivers of the type 2 inflammation that plays a major role in atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyposis.
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
Clinical Manifestations and Prognostic Impact of Anemia in Myelofibrosis
2
Trump Announces Pricing Deals With 9 Drugmakers, Expanding Most-Favored-Nation Drug Pricing Strategy
3
Understanding Myelofibrosis and the Central Role of JAK Pathway Dysregulation
4
More Dose Adjustments, Similar Outcomes: Ribociclib vs Palbociclib in Practice
5




































































































































































































